Blood Tests
For Patients on Treatment
Blood tests and safety checks for patients on treatment
Convenience of Testing
Most of these blood tests can be conveniently done at your GP’s office. However, if you would prefer to have them done in the hospital, this can be arranged upon request.
For blood tests conducted through the HSE system via your GP, please note they are not automatically accessible to your rheumatologist unless they are sent via secure email or brought in physically.
We encourage you to ensure your lab results are made available to your rheumatologist.
Regular testing and monitoring ensure that your treatment remains safe and effective.
If you have any questions or concerns, don’t hesitate to discuss them with your doctor.
Blood Tests
A typical screening panel includes a full blood count (FBC), SMAC (comprehensive metabolic panel), C-reactive protein (CRP), and annual monitoring of lipids, glucose, and HbA1c.
Methotrexate (and other DMARDs like Leflunomide and Sulfasalazine)
We usually recommend checking blood tests one month after starting Methotrexate (or another DMARD) and one month after any dose increase.
Once your treatment is stable, blood tests are typically needed every 3 months, although the interval may be extended to 6 months for certain patients on established treatment. If you're unsure about your schedule, ask your rheumatologist.
Biologics
Blood tests are less frequent but may still be required every 3–6 months, depending on your specific medication and health status. Common subcutaneous biologics used in rheumatoid arthritis include:
- Adalimumab (commonly known as Humira, Amgevita)
- Etanercept (commonly known as Enbrel, Benepali)
- Certolizumab pegol (commonly known as Cimzia)
- Golimumab (commonly known as Simponi)
- Tocilizumab (commonly known as RoActemra)
- Abatacept (commonly known as Orencia)
JAK inhibitors
Blood tests are typically done one month after starting treatment and then every 3–6 months thereafter, depending on your specific health status and the medication prescribed (e.g., tofacitinib, baricitinib, upadacitinib, and filgotinib).
Hydroxychloroquine and Eye Monitoring
Hydroxychloroquine is widely used for rheumatologic conditions such as rheumatoid arthritis and lupus due to its anti-inflammatory effects.
However, prolonged use of Hydroxychloroquine can, in rare cases, lead to retinal damage.
To ensure eye health:
- Initial Screening: A baseline eye examination is recommended within the first year of starting Hydroxychloroquine.
- Ongoing Monitoring: Annual eye examinations are recommended after 5 years of continuous use, or sooner if advised by your doctor.
Screening Tests
These eye examinations typically include:
- Optical coherence tomography (OCT) to detect early retinal changes.
- Visual field testing to assess peripheral vision.
Eye testing can be done by an ophthalmologist or, in certain situations, by an optometrist with the appropriate training and equipment for Hydroxychloroquine screening.
Appointments
Patients can request an appointment here.
Repeat Prescriptions
Existing patients can request prescriptions here.
Location
We are located at the Blackrock Health Galway Clinic.
Our Affiliations
